Morgan & Morgan announces that a class action has been filed in the United States District Court for the District of New Jersey on behalf of all purchasers of Immunomedics, Inc. common stock (Nasdaq:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934. If you purchased Immunomedics during the Class Period, you may, no later than April 28, 2014, request that the Court appoint you lead plaintiff of the proposed class. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. Immunomedics, Inc. (NASDAQ:IMMU) stock opened at $4.66 in last session, and closed at $4.93, while the day range of IMMU stock is $4.61-$5.05.The stock showed a negative weekly performance of -5.46%.
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) were the target of some unusual options trading on Tuesday. Stock investors acquired 3,415 put options on the company, AmericanBankingNews.com reports. This represents an increase of 259% compared to the average daily volume of 950 put options. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock opened at $6.04-$32.00, in last session and closed at $30.04, by gained 6.56%.The 52 week range was $6.04-$32.00.Company’s market capitalization is $2.74 billion.
Halozyme Therapeutics (NASDAQ:HALO) released its earnings data on Thursday. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.02, American Banking News.com reports. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $21.80 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The company’s quarterly revenue was down 42.7% on a year-over-year basis. Halozyme Therapeutics, Inc. (NASDAQ:HALO) stock gained 8.16% and finished the last session at $8.16.The EPS of the stock remained -0.59.Company’s market capitalization is $1.82 billion.
Peregrine Pharmaceuticals (NASDAQ:PPHM) reported that it will declare financial results for the third quarter of fiscal year (FY) 2014 on March 7, 2014 before market opens and will host a conference call and webcast at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock opened the session at $1.85, and closed the session at $1.91.The 52 week range of the PPHM stock remained $1.11-$2.06 and the day range was $1.80-$2.06.